Last reviewed · How we verify
ARM B: IV iron + epoietin zeta sequence
This combination therapy replenishes iron stores and stimulates red blood cell production to treat anemia.
This combination therapy replenishes iron stores and stimulates red blood cell production to treat anemia. Used for Chemotherapy-induced anemia, Anemia of chronic disease.
At a glance
| Generic name | ARM B: IV iron + epoietin zeta sequence |
|---|---|
| Sponsor | Centre Francois Baclesse |
| Drug class | Iron supplement + Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis |
| Modality | Small molecule |
| Therapeutic area | Hematology/Oncology |
| Phase | FDA-approved |
Mechanism of action
Intravenous iron provides essential iron substrate for hemoglobin synthesis, while epoietin zeta (a recombinant erythropoietin) stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells. Together, they address both iron deficiency and inadequate erythropoietin-mediated red blood cell production.
Approved indications
- Chemotherapy-induced anemia
- Anemia of chronic disease
Common side effects
- Hypertension
- Thromboembolism
- Injection site reactions
- Headache
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: